Laura Benjamin
Direktor/Vorstandsmitglied bei ALLARITY THERAPEUTICS, INC.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Thomas Jensen | M | 46 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 20 Jahre |
Gerald McLaughlin | M | 56 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 2 Jahre |
Steen Meier Knudsen | M | 63 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 20 Jahre |
Joseph Vazzano | M | 40 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 1 Jahre |
Joan Brown | F | 71 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 3 Jahre |
Chrystyna Stecyk | F | 61 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
Zuie Chin Huang | M | 58 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
Peter Bisgaard | M | 50 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
Marie Foegh | M | 82 |
Allarity Therapeutics A/S
Allarity Therapeutics A/S Pharmaceuticals: MajorHealth Technology Allarity Therapeutics A/S is a biotechnology company, which engages in the research and development of anti-cancer drugs. Its product pipeline includes LiPlaCis, 2X-121, 2X-111, irofulven phase 2, and APO010.The company was founded by Steen Meier Knudsen and Peter Buhl Jensen in 2004 and is headquartered in Hoersholm, Denmark. | 6 Jahre |
Hagop Youssoufian | M | 67 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | 4 Jahre |
David Malek | M | 47 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | 6 Jahre |
Sarah Wang | F | - |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
Yunjoon Kim | M | - |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
Rebecca Wolfe | F | - |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Charles Ballantyne | M | 64 |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | 2 Jahre |
Matthew Osborne | M | - |
Oncxerna Therapeutics, Inc.
Oncxerna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oncxerna Therapeutics, Inc. develops oncology drugs. The firm uses RNA-based biomarker platform. It focuses on clinical-stage therapies. The company was founded by Laura E. Benjamin in 2018 and is headquartered in Boston, MA. | 1 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 15 | 93,75% |
Dänemark | 6 | 37,50% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Laura Benjamin
- Persönliches Netzwerk